Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Razvan Balotescu

Internal Medicine Ponte Vedra Beach, FL Medical Doctor

NPI 1669426094 CMS profile 75510

228 Ponte Vedra Park Dr Ste 500, Ponte Vedra Beach, FL 32082

Open in the dashboard

General payments

$10,010

549 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Razvan Balotescu of Ponte Vedra Beach, FL is reported in the CMS Open Payments database as having received $10,010 across 549 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,170 53
2024 General $1,359 67
2023 General $1,150 66
2022 General $1,500 83
2021 General $2,338 133
2020 General $1,192 76
2019 General $1,302 71

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Razvan Balotescu
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Razvan Balotescu were reported at $1,170. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Razvan Balotescu Internal Medicine median Middle half National median
2019 $1,302 $159 $48–$570 $163
2020 $1,192 $119 $33–$402 $114
2021 $2,338 $135 $37–$521 $132
2022 $1,500 $141 $42–$496 $149
2023 $1,150 $149 $45–$519 $160
2024 $1,359 $154 $47–$537 $164
2025 $1,170 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,024 59 payments
  2. AbbVie, Inc. $784 56 payments
  3. GlaxoSmithKline, LLC. $766 41 payments
  4. AstraZeneca Pharmaceuticals LP $688 40 payments
  5. Amarin Pharma Inc. $607 34 payments
  6. Pfizer Inc. $566 30 payments
  7. Lilly USA, LLC $534 33 payments
  8. OptiNose US, Inc. $378 20 payments
  9. Amgen Inc. $372 22 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $365 17 payments
  11. Other $3,926 197 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,995 548 payments
  2. Education $15 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $819 47 payments
  2. TRELEGY ELLIPTA $692 36 payments
  3. Vascepa $590 33 payments
  4. FARXIGA $523 31 payments
  5. RYBELSUS $513 32 payments
  6. NURTEC ODT Pain $437 20 payments
  7. Xhance $378 20 payments
  8. NURTEC ODT Primary Care $365 14 payments
  9. XARELTO $307 18 payments
  10. ELIQUIS $304 15 payments
  11. Other $7,937 448 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 81 drugs

Part D claims

3,351

Median for Internal Medicine: 777

Drug cost

$304,046

Median for Internal Medicine: $73,373

Branded share of claims

17.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 47 $62,331
Ozempic Semaglutide Brand 52 $54,291
Mounjaro Tirzepatide Brand 38 $39,253
Jardiance Empagliflozin Brand 28 $32,652
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 30 $27,770
Trulicity Dulaglutide Brand 18 $19,136
Myrbetriq Mirabegron Brand 20 $18,770
Movantik Naloxegol Oxalate Brand 11 $6,169
Synthroid Levothyroxine Sodium Brand 50 $4,722
Omega-3 Acid Ethyl Esters Generic 13 $1,835

The 10 drugs with the highest cost, of 81 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$122,627

Of which drugs: $4,534

Medicare patients

411

Average age 75

Services billed

2,950

200 women, 211 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 42%
Ischemic heart disease 26%
Chronic kidney disease 23%
Depression 22%
Diabetes 19%
Osteoporosis 18%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 28 28 $2,291

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $88
$88 — —
Xhance
  • OptiNose US, Inc. $79
$79 — —
VRAYLAR
  • AbbVie, Inc. $73
$73 — —
NURTEC ODT
  • PFIZER INC. $72
$72 — —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $69
$69 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

549 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record